THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.”VANCOUVER, Canada, April 07, 2026 (GLOBE NEWSWIRE) -- ...
The MarketWatch News Department was not involved in the creation of this content. -- $15 million upfront with a milestone-driven potential additional $15 million related to the Company's anticipated ...
Québec Innovative Materials (QIMCF) has announced an agreement with Research Capital Corporation (RCC) as the sole underwriter and bookrunner for a "bought deal" private placement, that consists of 16 ...
Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study results, that support development ...
-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The private placement also ...
$5M private placement financing with participation from new and existing stockholders and a strategic partner with deep obesity expertise significantly strengthens Company’s financial position as the ...
BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a ...
Kyle Samani, Managing Partner of Multicoin Capital, to Become Chairman of the Board of Directors, Effective Upon the Closing of the Private Placement Private Placement is the Largest Solana-focused ...
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, ...
$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market ...